When rashes occur following exposure to immune checkpoint inhibitors (ICIs), those with darker skin tones may face greater diagnostic delays, greater rates of referral to dermatologists, and a higher likelihood of undergoing biopsy, according to a literature review that assessed how cutaneous ICI-related adverse events are managed in skin of color (SoC).
Overall, the collated data suggested that t...
Patterns detected: ARC-0043 Motte-and-Bailey, ARC-0024 Ambiguity
The review found that patients with darker skin tones are more likely to be referred to dermatologists and undergo biopsy when they develop rashes following exposure to ICIs. However, the conclusions are preliminary as only a handful of studies have directly compared the rate and severity of cutaneous toxicities between races or skin tones. The review was limited to publications evaluating rash or other skin toxicities associated w...